Wael Taha, MD
Endocrinology, Diabetes & Metabolism · Detroit, MINPI 1578501748
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (39.5%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 31 manufacturers reported payments, led by Medtronic at 33.8% of the total. Reporting peaked in 2019 at $6,591 and has fallen 68.7% since, to $2,064 in 2025.
Across 200 payments — averaging $60.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$4K
- Corcept Therapeutics$4K
- Synthes GmbH$2K
- Novo Nordisk$417
- Amgen$336
- AstraZeneca$194
- plus $2K from 25 others
What the payments were for
- Consulting fees$2,25019%
- Speaking & faculty fees$4324%
- Travel & lodging$4,74639%
- Food & beverage$4,52438%
- Education$180%
- Other$500%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 54 | $4,061 |
| Corcept Therapeutics | 8 | $3,627 |
| Synthes GmbH | 2 | $1,798 |
| Novo Nordisk | 34 | $417 |
| Amgen(2 entities) | 17 | $336 |
| AstraZeneca(2 entities) | 12 | $194 |
| Neurocrine Biosciences, Inc. | 3 | $188 |
| Lilly USA, LLC | 13 | $186 |
| Radius Health, Inc. | 5 | $178 |
| Ipsen Biopharmaceuticals, Inc | 6 | $116 |
| Johnson & Johnson(2 entities) | 8 | $115 |
| Pfizer | 5 | $91 |
| Madrigal Pharmaceuticals | 2 | $79 |
| Abbott | 2 | $74 |
| Ultragenyx Pharmaceutical Inc. | 3 | $68 |
| Dexcom, Inc. | 3 | $57 |
| Recordati_rare_diseases_inc. | 2 | $51 |
| Amarin Pharma, Inc. | 2 | $47 |
| Shire North American Group Inc | 3 | $46 |
| Sequel Med Tech, LLC | 2 | $38 |
| Insulet Corporation | 2 | $34 |
| Sanofi-aventis U.S. LLC | 2 | $31 |
| Exact Sciences | 1 | $29 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $29 |
| Ascendis Pharma Endocrinology Inc | 1 | $28 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Zealand Pharma US, Inc. | 1 | $20 |
| Antares Pharma, Inc. | 1 | $18 |
| Viiv Healthcare Company | 1 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
| Cardiovascular Systems Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Korlym$3,498
- Minimed 670G System$1,362
- MINIMED 780G$1,245
- CRENESSITY$135
- Tymlos$121
- MINIMED 770G$113
How this compares
$12,020 in reported general payments places this provider in the 80th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.
See all endocrinology, diabetes & metabolism providers in Michigan →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 190 | $245,263 |
| TrulicityDulaglutide | 129 | $148,037 |
| MounjaroTirzepatide | 79 | $86,757 |
| JardianceEmpagliflozin | 92 | $80,826 |
| RybelsusSemaglutide | 38 | $57,654 |
| FarxigaDapagliflozin Propanediol | 61 | $55,132 |
| TymlosAbaloparatide | 18 | $46,087 |
| Teriparatide | 11 | $31,883 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $22,329 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 16 | $12,522 |
| TradjentaLinagliptin | 12 | $10,138 |
| Humalog Kwikpen U-100Insulin Lispro | 44 | $9,740 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 62 | $8,612 |
| HumalogInsulin Lispro | 48 | $7,990 |
| Novolog FlexpenInsulin Aspart | 28 | $7,555 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $417 | $305,009239 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $186 | $242,784256 claims |
| AstraZenecaFarxiga | $194 | $55,13261 claims |
| Radius Health, Inc.Tymlos | $178 | $46,08718 claims |
| Sanofi-aventis U.S. LLCLantus | $31 | $1,49213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.
Other endocrinology, diabetes & metabolism in Detroit
- Henry BoneDetroit$120K
- Shobana AthimulamDetroit$14K
- Berhane SeyoumDetroit$11K
- Lowell SchmeltzFarmington Hills$1.3M
- George GrunbergerBloomfield Hills$931K
- Gary EdelsonFarmington Hills$503K
- Michael BrennanSaint Clair Shores$433K
- Jamal HammoudFlint$386K
- Abdulsalam Al KassabRochester Hills$351K
- Richard AuchusAnn Arbor$250K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.